Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Heart Lung ; 43(3): 213-8, 2014.
Article in English | MEDLINE | ID: mdl-24661743

ABSTRACT

OBJECTIVES: The present study explored the experiences of people living with advanced heart failure (HF) to determine the extent to which (1) psychosocial resources relevant to HF patients were qualitatively reported, and (2) to determine the extent to which psychosocial resources were correlates of subsequent well-being as assessed by validated quantitative measures. BACKGROUND: HF is a serious life-limiting illness that involves impaired heart functionality. Patients commonly face severe physical fatigue and frequently endure disabling depression. Individuals with HF often report the use of social support and religion/spirituality (R/S) as helpful, but little work has systematically linked their reliance on these resources and well-being. METHODS: 111 participants completed four open-ended questions to assess aspects of living with HF. Open-ended questions were coded to identify psychosocial resources: positive meaning, gratitude, R/S, social support, and medical resources. Data were collected once and then again 3 months later. Participants also completed measures of well-being, including religious meaning, life meaning, satisfaction with life, depressive symptoms, death anxiety, and health-related quality of life. Bivariate correlations were used to relate psychosocial resources and well-being. RESULTS: Patients reported many psychosocial resources, particularly positive meaning, R/S, social support, and medical resources. Positive meaning and R/S were inversely linked with depressive symptoms. R/S was also related to less death anxiety, while social support was related to higher anxiety about death three months later. CONCLUSIONS: Findings advance our understanding of the struggles HF patients experience and the roles of psychosocial resources such as meaning and gratitude in alleviating these struggles. Results may help explain how resources like R/S and social support may influence well-being.


Subject(s)
Depression , Heart Failure/psychology , Personal Satisfaction , Quality of Life , Social Support , Adult , Aged , Anxiety , Female , Humans , Male , Middle Aged , Religion and Psychology
2.
J Relig Health ; 53(2): 579-90, 2014 Apr.
Article in English | MEDLINE | ID: mdl-23616124

ABSTRACT

We examined relationships between seven dimensions of religion/spirituality (RS) (forgiveness, daily spiritual experiences, belief in afterlife, religious identity, religious support, public practices, and positive RS coping) and three dimensions of well-being (physical, mental, and existential) in a sample of 111 patients with advanced chronic heart failure. Participants completed questionnaires at baseline and 3 months later. Results showed that fairly high levels of RS were reported on all seven dimensions. Furthermore, RS dimensions were differentially related to well-being. No aspect of RS was related to physical well-being, and only a few aspects were related to mental well-being. Forgiveness was related to less subsequent depression, while belief in afterlife was related to poorer mental health. All aspects of RS were related to at least one aspect of existential well-being. In particularly, daily spiritual experiences were linked with higher existential well-being and predicted less subsequent spiritual strain. These results are consistent with the view that in advanced disease, RS may not affect physical well-being but may have potent influences on other aspects of well-being, particularly existential aspects.


Subject(s)
Adaptation, Psychological/physiology , Attitude to Health , Heart Failure/psychology , Spirituality , Aged , Chronic Disease , Female , Follow-Up Studies , Forgiveness , Humans , Male , Ohio , Religion and Psychology , Severity of Illness Index , Surveys and Questionnaires
3.
Qual Life Res ; 17(1): 21-6, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18034319

ABSTRACT

OBJECTIVE: The present study examined (1) whether particular coping strategies used to deal with congestive heart failure (CHF) are related to meaning in life across time, and (2) whether meaning in life mediates the effect of coping on health-related quality of life. METHODS: A sample of 155 CHF patients received questionnaire packets at two time points, 6 months apart. Main outcome measures included Meaning in Life and Mental and Physical Health-Related Quality of Life (HRQOL). RESULTS: Coping (particularly acceptance/positive reinterpretation and religious coping) was not only related to meaning in life, but also to increased meaning over time. Further, meaning in life was related to both mental and physical components of HRQOL. However, coping was minimally related to HRQOL and its effects were not mediated by meaning in life. CONCLUSIONS: These results add to accumulating evidence that life meaning is important in the context of living with a chronic, life-threatening illness. Further, coping--especially acceptance and religious coping--is related to increased life meaning over time in the context of life limiting illness.


Subject(s)
Adaptation, Psychological , Heart Failure/psychology , Personal Satisfaction , Quality of Life/psychology , Health Status , Humans , Surveys and Questionnaires , United States
4.
Circ Res ; 86(8): 834-40, 2000 Apr 28.
Article in English | MEDLINE | ID: mdl-10785504

ABSTRACT

The beta(2)-adrenergic receptor (beta(2)AR) exists in multiple polymorphic forms with different characteristics. Their relevance to heart failure (HF) physiology is unknown. Cardiopulmonary exercise testing was performed on 232 compensated HF patients with a defined beta(2)AR genotype. Patients with the uncommon Ile164 polymorphism had a lower peak VO(2) (15.0+/-0.9 mL. kg(-1). min(-1)) than did patients with Thr164 (17.9+/-0.9 mL. kg(-1). min(-1), P<0.0001). The percentage achieved of predicted peak VO(2) was also lower in patients with Ile164 (62. 3+/-4.5% versus 71.5+/-5.1%, P=0.045). The relative risk of a patient having a VO(2)

Subject(s)
Exercise , Heart Failure/genetics , Heart Failure/physiopathology , Polymorphism, Genetic , Receptors, Adrenergic, beta-2/genetics , Alleles , Female , Genetic Predisposition to Disease , Humans , Male , Middle Aged
5.
Am Heart J ; 139(3): 537-42, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10689270

ABSTRACT

BACKGROUND: The Gly16 beta(2)-adrenergic receptor (beta(2)AR) polymorphism is a common variant of the beta(2)AR that displays depressed function caused by enhanced receptor downregulation in vitro compared with the Arg16 receptor. METHODS AND RESULTS: We studied 20 healthy, normotensive, nonsmoking white individuals who were homozygous for either the Arg16 (n = 10) or the Gly16 (n = 10) genotype. Plethysmographic lower-limb blood flow, blood pressure, and 2-dimensional echocardiograms were recorded at baseline and after 15-minute incremental infusions of terbutaline (100 to 300 ng/kg per minute). Baseline heart rates, blood pressures, and flows were similar in both groups, but at the maximum dose of terbutaline, limb blood flow was less (P <.05), calculated vascular resistance was greater (P <.05), and systolic and diastolic blood pressures were greater in patients with Gly16 than in those with Arg16 (both P <.05). In contrast, terbutaline-stimulated heart rates were not different. In a separate group of 20 homozygous individuals (12 Arg16, 8 Gly16), there were no differences in 2-dimensional echocardiographically determined ventricular function. CONCLUSIONS: We conclude that the Gly16 beta(2)AR polymorphism imparts attenuated vasodilatory responses to catecholamines in normal human beings and is an important genetic component in the regulation of peripheral blood flow and systemic arterial pressure.


Subject(s)
Adrenergic beta-Agonists/pharmacology , Amino Acid Substitution/genetics , Hemodynamics/genetics , Polymorphism, Genetic/physiology , Receptors, Adrenergic, beta-2/genetics , Adrenergic beta-2 Receptor Agonists , Adult , Blood Pressure/drug effects , Blood Pressure/genetics , Echocardiography , Female , Genotype , Heart Rate/drug effects , Heart Rate/genetics , Hemodynamics/drug effects , Homozygote , Humans , Leg/blood supply , Male , Observer Variation , Plethysmography , Reference Values , Regional Blood Flow/drug effects , Regional Blood Flow/genetics , Stroke Volume/drug effects , Stroke Volume/genetics , Terbutaline/pharmacology , Vascular Resistance/drug effects
6.
J Card Fail ; 6(4): 359-68, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11145761

ABSTRACT

Despite conventional therapy, there is still much room for improvement in the prognosis of patients with chronic systolic heart failure. Evidence supports a role for endothelin-1 (ET-1), a potent vasoconstrictor, in the pathophysiology of heart failure. Given its potentially deleterious effects, the optimal treatment of heart failure may need to include efforts directed toward antagonizing this hormone. In support of this notion, the use of ET receptor antagonists produces a number of beneficial effects in heart failure, including both improvements in hemodynamics and reductions in the levels of other vasoconstricting neurohormones. There are at least 2 receptors for ET-1 (the ET-A and ET-B receptor), and the effects of ET-1 binding differ depending on the receptor involved. It is still unclear whether blockade of the ET-A receptor alone or the combined blockade of both the ET-A and ET-B receptors will be most efficacious as a therapeutic strategy. Long-term benefits have been achieved with the use of a mixed ET-A/B receptor antagonist, when added to standard triple-drug therapy, in patients with severe heart failure. We await the results of ongoing trials to determine if these agents will fulfill the promise of adding substantial incremental benefit to the treatment of the disease.


Subject(s)
Endothelin Receptor Antagonists , Endothelin-1/physiology , Heart Failure/drug therapy , Heart Failure/etiology , Bosentan , Carboxylic Acids/pharmacology , Carboxylic Acids/therapeutic use , Chronic Disease , Heart Failure/physiopathology , Humans , Indans/pharmacology , Indans/therapeutic use , Peptides, Cyclic/pharmacology , Peptides, Cyclic/therapeutic use , Prognosis , Pyridines/pharmacology , Pyridines/therapeutic use , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Receptors, Endothelin/classification , Sulfonamides/pharmacology , Sulfonamides/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...